BackProtagonist Therapeutics Overview

Protagonist Therapeutics Other Current Assets

Protagonist Therapeutics's other current assets is $11M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$11.16M
65.20% YoYΔ $-20.91M vs prior year quarter

Peer average / median

Loading

Protagonist Therapeutics Other Current Assets History

Loading

Protagonist Therapeutics vs. peers: Other Current Assets Comparison

Loading

Protagonist Therapeutics Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Protagonist Therapeutics (PTGX) FAQ

Protagonist Therapeutics's other current assets stands at $11M as of June 2026. That compares with $32M in the prior-year period — down 65.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Protagonist Therapeutics reported $11M in other current assets versus $32M a year earlier — a 65.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $32M in the prior-year period — down 65.2% year over year. Sustained growth in other current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Protagonist Therapeutics's other current assets evolved across reporting periods, while the comparison chart places PTGX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current assets is commonly used to spot outliers. Protagonist Therapeutics's reading of $11M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.